natgillin/translations-raw huggingface dataset:
Netupitant-tabletter Mikrokrystallinsk cellulose (E460) Saccharoselaurylsyreestere Povidon K-30 Croscarmellosenatrium
Netupitant tablets Microcrystalline cellulose (E460) Sucrose lauric acid esters Povidone K-30
Netvax injektionsvæske, emulsion til kyllinger
Netvax emulsion for injection for chickens
Netwax indeholder små mængder af et toksoid fra C. perfringens type A. Når en kylling vaccineres med Netwax opfatter dyrets immunsystem toksoidet som "fremmed" og reagerer ved at danne antistoffer imod det.
Netvax contains small amounts of a toxoid from C. perfringens type A. When it is given to a chicken, its immune system recognises the toxoid as ‘foreign’ and makes antibodies against it.
Neulasta 6 mg injektionsvæske Pegfilgrastim
Neulasta 6 mg injection Pegfilgrastim
Neulasta 6 mg injektionsvæske, opløsning i fyldt injektionssprøjte pegfilgrastim
Neulasta 6 mg solution for injection in a pre-filled syringe pegfilgrastim
Neulasta 6 mg injektionsvæske, opløsning Pegfilgrastim
Neulasta 6 mg solution for injection Pegfilgrastim
Neulasta 6 mg injektionsvæske, opløsning.
Neulasta 6 mg solution for injection.
Neulasta anvendes til at begrænse varigheden af neutropeni og forekomsten af febril neutropeni (neutropeni med feber).
Neulasta is used to reduce the duration of neutropenia and the occurrence of febrile neutropenia (neutropenia with fever).
Neulasta anvendes til cancerpatienter til at afhjælpe nogle af bivirkningerne ved den behandling, de modtager.
Neulasta is used in cancer patients to help with some of the side effects of their treatment.
Neulasta blev undersøgt i to hovedundersøgelser med deltagelse af 467 patienter med brystkræft, der blev behandlet med cytotoksisk kemoterapi.
Neulasta has been studied in two main studies involving 467 patients with breast cancer who were being treated with cytotoxic chemotherapy.
Neulasta bør altid anvendes i nøje overensstemmelse med Deres læges instruktioner.
Always take Neulasta exactly as your doctor has told you.
Neulasta bør ikke anvendes hos patienter, der kan være overfølsomme (allergiske) over for pegfilgrastim eller andre af indholdsstofferne.
Neulasta should not be used in people who may be hypersensitive (allergic) to pegfilgrastim or any of the other ingredients.
Neulasta bør ikke anvendes under graviditeten og til kvinder i den fertile alder, som ikke anvender sikker kontraception.
Neulasta is not recommended during pregnancy and in women of childbearing potential not using contraception.
Neulasta er en klar, farveløs injektionsvæske, opløsning i en fyldt injektionssprøjte (6 mg/0,6 ml).
Neulasta is a clear, colourless solution for injection in a pre-filled syringe (6 mg/0.6 ml).
Neulasta er en opløsning til injektion, som indeholder det aktive stof pegfilgrastim.
Neulasta is a solution for injection that contains the active substance pegfilgrastim.
Neulasta gives som en injektion i vævet lige under huden (subkutan injektion).
Neulasta is given as an injection into the tissue just under the skin (subcutaneous injection).
Neulasta indeholder sorbitol (E 420) og natriumacetat
Neulasta contains sorbitol (E420) and sodium acetate
Neulasta indeholder sorbitol (en form for sukker).
Neulasta contains sorbitol (a type of sugar).
Neulasta injiceres subkutant.
Neulasta is injected subcutaneously.
Neulasta kan udsættes for stuetemperatur (ikke over 30 C) i maksimalt en enkelt periode på op til 72 timer.
Neulasta may be exposed to room temperature (not above 30C) for a maximum single period of up to 72 hours.
Neulasta må ikke administreres til patienter med overfølsomhed over for pegfilgrastim eller filgrastim i anamnesen.
Do not administer Neulasta to patients with a history of hypersensitivity to pegfilgrastim or filgrastim.
Neulasta opbevaret ved stuetemperatur i mere end 72 timer skal kasseres.
Neulasta left at room temperature for more than 72 hours should be discarded.
Neulasta påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner.
Neulasta has no or negligible influence on the ability to drive and use machines.
Neulasta sikkerhed og virkning er ikke blevet undersøgt hos patienter i behandling med højdosis kemoterapi.
The safety and efficacy of Neulasta have not been investigated in patients receiving high dose chemotherapy.
Neulasta skal seponeres permanent hos patienter med klinisk signifikant overfølsomhed.
Permanently discontinue Neulasta in patients with clinically significant hypersensitivity.
Neulasta var lige så effektivt som filgrastim til at nedsætte varigheden af svær neutropeni.
Neulasta was as effective as filgrastim in reducing the duration of severe neutropenia.
Neulastas sikkerhed og virkning hos de novo AML-patienter < 55 år med cytogenetik t(15;17) er ikke klarlagt.
The safety and efficacy of Neulasta administration in de novo AML patients aged  55 years with cytogenetics t(15;17) have not been established.
Neupopeg 6 mg injektionsvæske i fyldt injektionssprøjte pegfilgrastim
Neupopeg 6 mg solution for injection in a pre-filled syringe pegfilgrastim
Neupopeg 6 mg injektionsvæske i fyldt pen pegfilgrastim
Neupopeg 6 mg solution for injection in a pre-filled pen pegfilgrastim
Neupopeg 6 mg injektionsvæske Pegfilgrastim
Neupopeg 6 mg injection Pegfilgrastim
Neupopeg 6 mg injektionsvæske, opløsning i en fyldt pen Pegfilgrastim
Neupopeg 6 mg solution for injection in a pre-filled pen Pegfilgrastim
Neupopeg 6 mg injektionsvæske, opløsning Pegfilgrastim
Neupopeg 6 mg solution for injection Pegfilgrastim
Neupopeg 6 mg injektionsvæske, opløsning, i fyldt pen.
Neupopeg 6 mg solution for injection in a pre-filled pen.
Neupopeg 6 mg injektionsvæske, opløsning.
Neupopeg 6 mg solution for injection.
Neupopeg er en injektionsvæske, opløsning i en fyldt injektionssprøjte (6mg/0,6ml).
Neupopeg is a solution for injection in a pre-filled syringe (6 mg/0.6 ml).
Neupopeg indeholder sorbitol (en form for sukker).
Neupopeg contains sorbitol (a type of sugar).
Neupopeg må udsættes for stuetemperatur (ikke over 30C) i maksimalt en enkelt periode på op til 72 timer.
Neupopeg may be exposed to room temperature (not above 30C) for a maximum single period of up to 72 hours.
neupro 1 mg/24 timer
neupro 1 mg/24 h
Neupro 1 mg/24 timer depotplaster
Neupro 1 mg/24 h transdermal patch
Neupro 1 mg/24 timer depotplaster rotigotin
Neupro 1 mg/24 h transdermal patch rotigotine
Neupro 2 mg/24 timer depotplaster
Neupro 2 mg/24 h transdermal patch
Neupro 2 mg/24 timer Neupro 4 mg/24 timer Neupro 6 mg/24 timer Neupro 8 mg/24 timer Depotplaster Rotigotin
Neupro 2 mg/24 h Neupro 4 mg/24 h Neupro 6 mg/24 h Neupro 8 mg/24 h Transdermal patch Rotigotine
neupro 2 mg/24 timer, 4 mg/24 timer, 6 mg/24 timer, 8 mg/24 timer
neupro 2 mg/24 h, 4 mg/24 h, 6 mg/24 h, 8 mg/24 h
neupro 3 mg/24 timer
neupro 3 mg/24 h
Neupro 3 mg/24 timer depotplaster
Neupro 3 mg/24 h transdermal patch
Neupro 3 mg/24 timer depotplaster rotigotin
Neupro 3 mg/24 h transdermal patch rotigotine
neupro 4 mg/24 timer
neupro 4 mg/24 h
Neupro 4 mg/24 timer depotplaster
Neupro 4 mg/24 h transdermal patch
Neupro 4 mg/24 timer depotplaster rotigotin
Neupro 4 mg/24 h transdermal patch rotigotine
neupro 6 mg/24 timer
neupro 6 mg/24 h
Neupro 6 mg/24 timer depotplaster
Neupro 6 mg/24 h transdermal patch
neupro 8 mg/24 timer
neupro 8 mg/24 h
Neupro 8 mg/24 timer depotplaster
Neupro 8 mg/24 h transdermal patch
Neupro 8 mg/24 timer depotplaster EU/1/05/331/010 EU/1/05/331/011
Neupro 8 mg/24 h transdermal patch EU/1/05/331/010
Neupro anvendes til behandling af restless legs-syndrom (RLS) hos voksne, en tilstand som karakteriseres ved ubehag i arme eller ben, trang til at bevæge dele af kroppen, søvnforstyrrelser, træthed eller døsighed i løbet af dagen.
Neupro is used to treat Restless Legs Syndrome (RLS) in adults that can be associated with discomfort in your legs or arms, urge to move around, sleep disturbance, tiredness or sleepiness during the day.
Neupro anvendes til behandling af tegn og symptomer på Parkinsons sygdom hos voksne enten alene eller i kombination med et lægemiddel, som kaldes levodopa.
Neupro is used to treat the signs and symptoms of Parkinson’s disease in adults either alone or in combination with the medicine called levodopa.
Neupro anvendes til behandling af:
Neupro is used to treat:
Neupro blev sammenlignet med ropinirol i to mindre undersøgelser, der blev gennemført efter lægemidlets godkendelse.
Two smaller studies comparing Neupro with ropinirole were completed after the medicine’s authorisation.
Neupro bør ikke anvendes af børn, da dets virkning og sikkerhed ikke er fastlagt hos børn.
Neupro should not be used by children because its safety and efficacy has not been established in children.
Neupro er et depotplaster.
Neupro is a transdermal patch.
Neupro er indiceret som monoterapi (dvs. uden levodopa) til behandling af tegn og symptomer på idiopatisk Parkinsons sygdom i tidlige stadier eller i kombination med levodopa, dvs. under hele sygdommens forløb og i de sene stadier, hvor virkningen af levodopa aftager eller bliver svingende, og der optræder udsving i den terapeutiske effekt (ved slutningen af hver dosis eller ”on-off”-udsving).
Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or ‘on-off’ fluctuations).
Neupro er til indgivelse gennem huden, og er et plaster, som sættes på huden.
Neupro is for transdermal use, a patch to be applied to the skin.
Neupro indeholder det aktive stof rotigotin.
Neupro contains the active substance rotigotine.
Neupro indeholder natriumpyrosulfit (E 223)
Neupro contains sodium metabisulphite (E223)
Neupro kan forårsage hudreaktioner såsom rødme og kløe.
Neupro can cause skin reactions, such as reddening and itching.
Neupro kan forårsage unormal tankegang og adfærd.
Neupro may cause abnormal thinking and behaviour.
Neupro kan gøre Dem meget døsig, og De falder måske i søvn meget pludseligt.
Neupro may make you feel very drowsy, and you may fall asleep very suddenly.
Neupro kan nedsætte blodtrykket, når De rejser Dem op; dette kan forværres af den medicin, som anvendes til at sænke blodtrykket. tage beroligende medicin (fx benzodiazepiner, lægemidler til behandling af psykiske forstyrrelser eller depression), mens De anvender Neupro.
Neupro may decrease blood pressure when you stand up; this effect may worsen by the medicine used to lower blood pressure. take sedating medicines (for example benzodiazepines, medicines used to treat mental conditions or depression) while you are using Neupro.
Neupro mg/24 timer
Neupro mg/24 h
Neupro skal klæbes på huden, så snart brevet er åbnet og den aftagelige beskyttelsesfilm fjernet.
You should stick Neupro onto your skin as soon as you have opened the sachet and removed the release liner.
Neupro var mere effektivt end placebo til behandling af Parkinsons sygdom.
Neupro was more effective than placebo in treating Parkinson’s disease.
Neuraceq 300 MBq/ml injektionsvæske, opløsning Florbetaben (18F)
Neuraceq 300 MBq/mL solution for injection Florbetaben (18F)
Neuraceq er en klar, farveløs væske til indsprøjtning.
Neuraceq is a clear, colourless solution for injection.
Neuraceq er et radioaktivt lægemiddel, der er indiceret til PET-scanning (positronemissionstomografi) af densiteten af neuritisk β-amyloidplak i hjernen hos voksne patienter med kognitiv funktionsnedsættelse, der bedømmes for Alzheimers sygdom og andre årsager til kognitiv funktionsnedsættelse.
Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment.
Neuraceq er til intravenøs anvendelse og til flerdosis.
Neuraceq is for intravenous use and for multidose use.
Neuraceq fås kun på recept, og PET-scanning med Neuraceq bør kun rekvireres af læger med erfaring i behandling af patienter med sygdomme såsom Alzheimers og andre former for demens.
Neuraceq can only be obtained with a prescription, and PET scans with Neuraceq should only be requested by doctors experienced in the management of patients with diseases such as Alzheimer’s and other dementias.
Neuraceq påvirker ikke evnen til at føre motorkøretøj og betjene maskiner.
Neuraceq has no known influence on the ability to drive and use machines.
neuraksialt
haematoma)
neuraksialt
haemorrhage
neuraksialt
Retroperito
neuralgi,
Pelvic pain
Neuralgi, feberkramper, neurologiske lidelser som f.eks. encefalomyelitis, neuritis og Guillain-Barré syndrom
Neuralgia, febrile convulsions, neurological disorders, such as encephalomyelitis and Guillain-Barré syndrome
Neuralgi, forbigående trombocytopeni
Neuralgia, transient thrombocytopenia.
Neuralgi, kramper, forbigående trombocytopeni
Neuralgia, convulsions, transient thrombocytopenia.
Neuralgi, kramper, forbigående trombocytopeni
Neuralgia, transient thrombocytopenia.
Neuralgi, paræstesi, konvulsioner, forbigående trombocytopeni
Neuralgia, paraesthesia, convulsions, transient thrombocytopenia.
neuro-
deafness
NeuroBloc anbefales ikke til børn i alderen 0-18 år, før der foreligger yderligere data.
NeuroBloc is not recommended in children aged 0-18 years until further data become available.
NeuroBloc anvendes til behandling af cervikal dystoni.
NeuroBloc is used to treat cervical dystonia.
NeuroBloc anvendes udelukkende på hospitaler og gives af en læge, som er bekendt med og har erfaring i behandling af cervikal dystoni og anvendelse af botulinum toksiner.
NeuroBloc is only used in hospitals, by a doctor who is familiar with and has experience in the treatment of cervical dystonia and in the use of botulinum toxins.
NeuroBloc blev sammenlignet med placebo (en virkningsløs behandling) i fire undersøgelser, der omfattede i alt 392 voksne med cervikal dystoni.
NeuroBloc has been compared with placebo (a dummy treatment) in four studies involving a total of 392 adults with cervical dystonia.
NeuroBloc bør ikke anvendes til personer, der kan være overfølsomme (allergiske) over for botulinum toxin eller andre af indholdsstofferne.
NeuroBloc should not be used in people who may be hypersensitive (allergic) to botulinum toxin or any of the other ingredients.
NeuroBloc bør ikke anvendes under graviditeten, medmindre kvindens kliniske tilstand kræver behandling med botulismetoksin type B.
NeuroBloc should not be used during pregnancy unless the clinical condition of the woman requires treatment with Botulinum Toxin Type B.
NeuroBloc er en opløsning til injektion, der indeholder det aktive stof botulinum toxin type B (5000 enheder [E] pr. milliliter).
NeuroBloc is a solution for injection that contains the active substance botulinum toxin type B (5000 units [U] per millilitre).
NeuroBloc må ikke anvendes til børn i alderen 0-18 år.
NeuroBloc is not to be used in children aged 0-18 years.
NeuroBloc må ikke anvendes til patienter med andre neuromuskulære (nerver og muskler) lidelser.
NeuroBloc must not be used in patients with other neuromuscular (nerve and muscle) disorders.
NeuroBlocs sikkerhed og virkning hos børn i alderen 0-18 år er endnu ikke klarlagt.
The safety and efficacy of NeuroBloc in children aged 0-18 years have not yet been established.
Neuroendokrine tumorer udgået fra mave-tarm-kanalen eller lungerne
Neuroendocrine tumours of gastrointestinal or lung origin
Neurofilament-abnormiteter, myelinisering og celleforstørrelse blev alle forbedret af behandlingen, selvom dysplastiske neuron-karakteristika persisterede, og der kun var beskedne ændringer i de dendritiske forgreningers tæthed og længde.
Neurofilament abnormalities, myelination and cell enlargement were all improved by the treatment, although dysplastic neuronal features persisted, and there were only modest changes in dendritic spine density and length.
NEUROLEPTIKA
Perphenazine
Neuroleptika (f.eks. phenothiaziner, sertindole, sultopride, klorpromazine, haloperidol, mesoridazine, pimozide eller thioridazine), antidepressiva.
Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine), antidepressive agents.
neuroleptika (stoffer, der bruges til behandling af sindslidelser) orale antikoagulantia
neuroleptics (substances used in the treatment of mental disorders) oral anticoagulants
neuroleptika (stoffer, der bruges til behandling af sindslidelser) orale antikoagulantia.
neuroleptics (substances used in the treatment of mental disorders) oral anticoagulants
neuroleptika og EVOTAZ kan
with EVOTAZ may result in
neuroleptika/antipsykotika (f.eks. clozapin, haloperidol og phenothiazin) til behandling af visse former for psykisk sygdom
neuroleptics/antipsychotics (clozapine, haloperidol, phenothiazine), used to treat some mental illnesses
neuroleptikasyndr
malignant syndrome
neuroleptikumsyndro
Status epilepticus
neuroleptikumsyndro
syndrome
Neurologisk:
Neurologic:
Neurologisk:
Neurological:
Neurologiske bivirkninger
Neurologic events
Neurologiske bivirkninger
Neurological events
Neurologiske forstyrrelser såsom encefalomyelitis, neuritis og Guillain- Barrés syndrom
Neurological disorders, such as encephalomyelitis, neuritis and Guillain Barré syndrome
Neurologiske forstyrrelser, såsom encefalomyelitis og Guillain Barrés syndrom.
Neurological disorders, such as encephalomyelitis, and Guillain Barré syndrome.
Neurologiske forstyrrelser, såsom encefalomyelitis og Guillain-Barrés syndrom.
Neurological disorders, such as encephalomyelitis, and Guillain Barré syndrome.
Neurologiske forstyrrelser, såsom encefalomyelitis, neuritis og Guillain Barrés-syndrom.
Neurological disorders, such as encephalomyelitis, neuritis and Guillain Barré syndrome.
Neurologiske forstyrrelser: Bevægelses- og koordinationsforstyrrelser, unormale fornemmelser såsom sovende fornemmelse, hukommelsestab, koncentrationsbesvær, talebesvær, svimmelhed.
Neurological disorders: movement and coordination disorders, abnormal sensations like pins and needles, memory loss, concentration difficulty, difficulty to talk, vertigo
Neurologiske hæ ndelser
Neurological events
neurologiske infektioner (inklusive viral meningitis)
neurological infections (including viral meningitis)
neurologiske infektioner (inklusive viral meningitis);
neurological infections (including viral meningitis);
Neurologiske lidelser (nervelidelser), f.eks. encephalopati (betændelse i det centrale nervesystem), neuritis (betændelse af nerver) og en form for lammelser kendt som Guillain- Barrés Syndrom
Neurological disorders such as encephalomyelitis (inflammation of the central nervous system), neuritis (inflammation of nerves) and a type of paralysis known a Guillain-Barré Syndrome
Neurologiske lidelser (nervelidelser), f.eks. encephalopati (betændelse i det centrale nervesystem), neuritis (betændelse af nerver) og en form for lammelser kendt som Guillain-Barrés Syndrom
Problems with your brain and nerves such as inflammation of the central nervous system (encephalomyelitis), inflammation of nerves (neuritis) or a type of paralysis known as ‘Guillain- Barré Syndrome’.
Neurologiske lidelser som
Neurological disorders such as
neurologiske reaktioner: ataxi (manglende koordinering) og kramper.
neurological reactions: ataxia (lack of coordination) and convulsions.
Neurologiske sygdomme
Neurologic disorders
Neurologiske sygdomme, f.eks. encefalomyelitis, neuritis og Guillain-Barré syndrom.
Neurological disorders, such as encephalomyelitis, neuritis and Guillain Barré syndrome
Neurologiske sygdomme, som kan resultere i stiv nakke, forvirring, følelsesløshed, smerter og svage lemmer, balancetab, tab af reflekser, paralysering af en del eller hele kroppen (encephalomyelitis, nervebetændelse, Guillain-Barré syndrom).
Neurological disorders that may result in stiff neck, confusion, numbness, pain and weakness of the limbs, loss of balance, loss of reflexes, paralysis of part or all the body (encephalomyelitis, neuritis, Guillain-Barré Syndrome).
neurologiske symptomer, synkope3, hypertoni, svimmelhed, paræstesi, krampeanfald, migræne
neurological symptoms, syncope3, hypertonia, dizziness, paraesthesia, seizures, migraine
neuromuskulær toksicitet
neuromuscular toxicity (including
neuromuskulær toksicitet (inklusive
neuromuscular toxicity (including
Neuromuskulære blokkere, narkotiske analgetika og forskellige kontrastmedier.
Neuromuscular blocking agents, narcotic analgesics, and various contrast media.
Neuronal phospholipidose forekom hos hunde behandlet i  3 måneder ved lavere systemisk eksponering end den, der opnås ved terapeutiske doser hos mennesker.
Neuronal phospholipidosis occurred in dogs dosed for  3 months at lower systemic exposures than those obtained at therapeutic doses in humans.
neuropati
agitation, insomnia,
Neuropati
Headache
Neuropati (brændende fornemmelse, dysæstesi, ”myrekryb”, gangforstyrrelser, hyperæstesi, hypæstesi, hypotoni, motorisk dysfunktion, muskelatrofi, muskelsvaghed, neuralgi, neuritis, perifer neuropati, neurotoksicitet, paræstesi, perifer motorisk neuropati, perifer sensorisk-motorisk neuropati, perifer sensorisk neuropati, parese fra perifere nerver, polyneuropati, føleforstyrrelser, brændende fornemmelse i huden).
Neuropathy (Burning sensation, Dysaesthesia, Formication, Gait disturbance, Hyperaesthesia, Hypoaesthesia, Hypotonia, Motor dysfunction, Muscle atrophy, Muscular weakness, Neuralgia, Neuritis, Neuropathy peripheral, Neurotoxicity, Paraesthesia, Peripheral motor neuropathy, Peripheral sensorimotor neuropathy, Peripheral sensory neuropathy, Peroneal nerve palsy, Polyneuropathy, Sensory disturbance, Skin burning sensation).
neuropati (inklusive perifer neuropati), svimmelhed, dysgeusi, døsighed
neuropathy (including peripheral neuropathy), dizziness, dysgeusia, somnolence
neuropati (nervelidelse)
neuropathy (disorder of the nerves)
Neuropati*, perifer sensorisk neuropati, dysæstesi*, neuralgi*
Neuropathies*, Peripheral sensory neuropathy, Dysaesthesia*, Neuralgia
neuropati;
neuropathy;
Neuropatid (25%)
Neuropathyd (25%)
Neuropatiens sværhedsgrad
Severity of neuropathy
Neuropatier*, motorisk neuropati*, bevidsthedstab (inkl. synkope), encefalopati*, perifer sensomotorisk neuropati, svimmelhed*, dysgeusi*, autonom neuropati
Gastrointestinal haemorrhage (inc mucosal)*, Abdominal distension, Dyspepsia, Oropharyngeal pain*, Gastritis*, Oral ulceration*, Abdominal discomfort, Dysphagia, Gastrointestinal inflammation*, Abdominal pain (inc gastrointestinal and splenic pain)*, Oral disorder
Neuropatier*, motorisk neuropati*, bevidsthedstab (inkl. synkope), encefalopati*, perifer sensomotorisk neuropati, svimmelhed*, dysgeusi*, autonom neuropati
Neuropathies*, Motor neuropathy*, Loss of consciousness (inc syncope), Encephalopathy*, Peripheral sensorimotor neuropathy, Dizziness*, Dysgeusia*, Autonomic neuropathy
Neuropatigrad
Severity of neuropathy
neuropatiske smerter (smerter som følge af beskadigelse af nerver).
neuropathic pain (pain due to nerve damage).
Neuropatiske sår skyldes en nervelidelse og ikke svigt af blodforsyningen til det berørte område.
Neuropathic ulcers are caused by a nerve problem, and not by a problem with the blood supply to the area affected.
Neuropsykiatrisk sikkerhed – metaanalyser og observationsstudier
Neuropsychiatric Safety Meta-analyses and Observational Studies:
Neuropsykiatrisk sikkerhedsstudie af forsøgspersoner med og uden tidligere psykisk forstyrrelse Vareniclin blev evalueret i et randomiseret, dobbeltblindet, aktivt og placebokontrolleret studie, der inkluderede forsøgspersoner med tidligere psykisk forstyrrelse (psykiatrisk kohorte, N=4074) og forsøgspersoner uden tidligere psykisk forstyrrelse (ikke-psykiatrisk kohorte, N=3984).
Neuropsychiatric Safety Study in Subjects with and without a History of Psychiatric Disorder: Varenicline was evaluated in a randomised, double-blind, active and placebo-controlled study that included subjects with a history of psychiatric disorder (psychiatric cohort, N=4074) and subjects without a history of psychiatric disorder (non-psychiatric cohort, N=3984).